fbpx

June 15, 2022

Oncology developments: the latest opinions on cancer treatments

*The translation of this article in French, Spanish, and German has been made through machine translation and has not been edited yet. we apologise for any inaccuracies.

Every month M3 Global Research conducts internal online surveys with our global Oncologist Panel about trending oncology topics.

This is a fun and quick way for oncologists around the world to share their opinions and expertise about the latest cancer treatments and oncology developments. Below we share the results from the three latest M3 oncology surveys: CBD and the future of Oncology, Non-invasive cancer diagnosis, Remote consultations for cancer patients

How do oncologists stay informed about the latest oncology developments?

Working as an oncologist is a demanding career path. It´s one of the most fast-changing medical fields, as new findings from laboratory research, clinical trials and market research around the world is constantly updating our understanding and best practices of how to prevent, diagnose, treat, and recover from cancer. Keeping up with the latest oncology developments and technologies, on top of taking care of patients, managing all the administrative tasks that comes along and dealing with the psychological pressure from work responsibilities and todays death rates – is indeed challenging.

WHO stated that ´cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths´. Moreover, the Global Cancer Observatory estimate that the number of new cancer cases in 2040 will go up to 28.9 million, compared to 19.3 million in 2020.

For an oncologist, these statistics may feel overwhelming and very concerning. However, governments, organisations, researchers, and physicians around the world are working hard to improve these numbers daily, which is one of the main reasons why the field of oncology is so fast-paced and ever-changing.

 

Although it is time-consuming and challenging to keep up with the latest oncology developments at times, it´s also one of the things that is exciting and rewarding about working as an oncologist according to Dr. Nayf Edrees; a UK-based pediatric oncologist and an M3 Global Research panel member. In an interview that M3 conducted with Dr. Edrees in 2020, he shared some insights about the rewards of being part of practicing and shaping future oncology developments.

“The healthcare landscape has changed greatly since I started my career (in 2015) because pediatric oncology is a fast-paced field and every day there’s a new medication or cancer treatment. One big change, especially in pediatric leukemia, is that in the 1950s and 1960s, the cure rate was only 10 percent and now it is close to 90 percent. In the last ten years, he’s seen more focus on target therapy. In just the last few years, I have seen much more focus on immunotherapy, which I believe will become one of the main treatments in the near future, for cancer in general.”
Oncology developments

One way of staying on top of up-and-coming cancer treatments and other oncology developments is to participate in healthcare market research, according to Dr. Nayf Edrees and Dr. Giancarlo Moscol. Dr. Moscol is a US based oncologist, who grew up in Peru, that M3 also interviewed back in 2019.

“Participating in market research studies is a good way to disconnect from the daily routine; I like to explore available studies during my free time and give myself plenty of time to focus on the studies and their future impact. I enjoy having the opportunity to provide my honest insight into where medicine is going and how I could apply it to my own practice. I look forward to the surveys that are applied to oncology because I get to learn about new products I may have missed learning about elsewhere, helping m3 keep updated about the latest cancer treatments.”.”
For many of the M3 Global Research panel members, these paid market research studies are a valuable source of information and a way to stay actively engaged in the development of future cancer treatments and technologies.

Due to the high demand from pharmaceutical companies and other life science organizations to gather real-life opinions and insights from both oncologists and cancer patients to make informed decisions about their products, devices, and services, M3 Global Research has a great number of market research studies available for oncologists.
The studies are well compensated and cover a wide variety of oncology topics, sub-specialties, and rare diseases within oncology. If you want to learn more about “Market research case study on rare disease treatments in oncology” you can read this M3 Blog article.

On top of paid market research studies, M3 Global Research offers oncologists, who are M3 Panel members, a way to voice their opinions about trending topics and important discussions about oncology in internal online surveys. This is a quick way to share one’s view about new cancer treatments, technologies, and other ongoing changes or developments within the oncology field. It is also a fun way to find out what other oncologists around the world think about these trending topics.

Here below you can see the summary of our latest internal oncology surveys and the results from February, March, and April 2022.

February 2022 - Is CBD the future of Oncology?

Should research and the medical use of CBD be prioritized in Oncology?

Respondents: 95

 

  • 53% think studies should focus only on how CBD helps patients get through cancer treatment instead of it being used as a treatment itself.
  • 23% believe that CBD research and treatments should be top priority for Oncology whereas 12% think it should not be a priority.
  • 9% think studies should focus on how CBD can help treat cancer instead of focusing on how it can support patients.

March 2022 - Non-invasive cancer diagnosis

Do you think technology will soon facilitate the detection of illnesses without invasive procedures? 

Respondents: 115 

 

  • 51% think this technology is the future of cancer with non-invasive cancer diagnosis, whereas 7% believe that technology alone is not enough to diagnose illnesses. 
  • 34% believe that whilst we should not rely on technology alone, non-invasive cancer diagnosis could improve survival rates for cancer patients significantly. 

April 2022- The digital shift

How does the shift towards remote consultations affect cancer patients and those suspected of having cancer?

Respondents: 93

  • 28% of the respondents believe that suspected cancer patients may delay their initial consultation, impacting the speed of their cancer diagnosis.
  • 28% think that suspected cancer patients are more likely to be seen sooner by their GP due to improved access via remote pathways.
  • 13% report thinking that remote consultations for cancer patients can reduce early detection, impacting successful patient outcomes.

Stay tuned, every three months M3 Global Research shares the results from out monthly online surveys that focus on future oncology developments.

Are you working as an oncologist and also want to stay-up-to date with the latest oncology developments and discussions?

Sign up for free with M3 Global Research and get access to a wide variety of paid market research studies and internal online surveys within your medical speciality.

Join your colleagues around the world today.

Leave a Reply

Join Today

Registration is free and only takes a few clicks

Panel Members

Check your available studies

latest posts